In the first six months of 2007 pharmacy chain 36.6 posted a $16.9 mln loss under IAS compared to net profit of $49.50 mln in the year-earlier period, the drug retailer said in a press release. The companys first-half consolidated sales shot up 78.6% to $390.5 mln and sales in the drug segment climbed by a record 92% to $302.9 mln. The retail chain attributes higher sales in the drug segment primarily to the large number of drugstores acquired in 2006. As news agencies wired earlier, in January-June 2006 the company generated net profit from net earnings derived from the sale of a stake in Veropharm during the IPO.
Read More...
[Source: Russian Stock Market Blog]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment